Private equity and strategic investors now face a new breed of healthcare asset: the VBC-enabled MSO. These companies — primary-care groups with Medicare Advantage risk, MSOs wrapping independent physicians, multi-specialty platforms with two-sided ACO contracts — present as recurring-revenue businesses with attractive margins and long growth runways.
They are also uniquely hard to diligence. Revenue is a function of attribution, benchmarks, and risk scores, not unit volume. Margins are a function of medical loss ratio, not gross-margin arithmetic. And durability is a function of contract terms most investors have never negotiated themselves.
Over dozens of diligence engagements, we have organized our framework around three dimensions — panel quality, contract durability, and clinical operating leverage. Get these right and the numbers will hold. Miss any of them and the next three years will not look like the last three.
Dimension one: Panel quality
A panel is not just a count of attributed lives. It is a portfolio of risk — and the composition of that portfolio determines whether the historical financials can repeat.
Risk score integrity
The single highest-leverage number in a VBC-enabled MSO is the panel's average risk score. A target with 1.15 risk adjusted factor and five years of compounding RAF growth is a very different business from a target with 0.95 RAF and flat or declining growth. We pressure-test RAF along three axes: level (compared to population benchmarks), trajectory (growth rate and deceleration), and composition (what diagnosis clusters are driving it). Targets whose RAF growth is concentrated in a small number of diagnosis categories — particularly those likely to draw CMS scrutiny — are flagged immediately.
Attrition and acquisition
Attributed lives churn. A high-performing MSO typically sees single-digit net attrition and double-digit growth from organic acquisition. A deteriorating MSO masks attrition with payer attribution changes, which are not durable. We look for three years of panel roll-forwards: who came in, who left, who aged in, who died. If the target cannot produce this view, the business is less understandable than the multiple implies.
Concentration
A panel dominated by a single payer or a single contract is a panel with one point of failure. We break down attributed lives by payer, contract, geography, and PCP cohort. Concentration over seventy percent in any dimension warrants a specific mitigation story.
Dimension two: Contract durability
The contracts are the business. A platform with three strong MA contracts is worth materially more than one with six mediocre ones — but only if the three are actually strong. "Strong" has a specific meaning.
Benchmark methodology
Not all benchmarks are created equal. A rebased benchmark that resets every year will compress margin as the organization improves. A benchmark anchored to a regional reference group can drift against the platform. We review the benchmark methodology in every material contract, model forward-year rebasing, and stress-test the platform's trend against the contract's.
Risk corridor and performance gates
Downside exposure is often layered behind quality gates, coding thresholds, or beneficiary engagement requirements. We model each of these under realistic execution assumptions — not the target's projections. A contract that looks like ten-percent upside on the first read is often four-percent upside after gates are applied honestly.
Renewal dynamics
The highest-value question in MA contract diligence is usually the simplest: what does the next renewal look like? We triangulate across payer posture, market dynamics, the platform's performance history, and comparable deals to stress-test the durability of current economics into the next cycle.
Dimension three: Clinical operating leverage
Panel quality and contract terms set the ceiling. Clinical operating leverage determines how close to the ceiling the business will actually get.
The care model
Every successful VBC-enabled MSO we have diligenced can describe its care model in one paragraph. It names the operating rhythm of the clinic: who sees which patients, how often, with what support staff, on what cadence. It names a high-risk program with defined enrollment and staffing. And it names the measurable outcomes the care model is built to produce. If leadership cannot produce that paragraph, the "clinical differentiation" in the CIM is narrative, not operating reality.
Provider behavior change
VBC platforms live or die on whether they can change the practice patterns of the physicians they employ or affiliate with. We look for evidence of this: documented changes in referral patterns, in prescribing, in post-acute utilization. A platform that has not moved any of these numbers is a platform that has not yet learned to do the job.
Scalability of the model
Can the care model be ported to a new market without losing performance? Can it absorb acquired physicians at reasonable cost? Can it support a ten-fold increase in attributed lives? These questions separate platforms with repeatable operating leverage from platforms that are succeeding on the strength of a specific founder team or a specific geography.
Putting it together
A VBC-enabled MSO is worth what the contracts, the panel, and the operating model together are worth over the life of those contracts. It is almost never worth the multiple the banker put on the cover of the CIM.
The strongest diligences we run produce a single chart: a bridge from reported EBITDA to what we call normalized risk-adjusted EBITDA, built by walking through each of the three dimensions and marking each component up or down. The target's reported number and our normalized number are rarely within twenty percent of each other. Sometimes the normalized number is higher. Sometimes lower. Either way, it is the number worth paying for.
VBC-enabled platforms are among the most attractive assets in healthcare today. They are also among the most frequently mispriced. Investors who invest the diligence effort to understand panel quality, contract durability, and clinical operating leverage — and who are honest with themselves about what each is worth — will find the deals that compound. Investors who do not, will underwrite revenue that never arrives.
If you are evaluating a VBC-enabled transaction, get in touch. We bring a focused diligence lens to buy-side and sell-side engagements.